Vancomycin is frequently under-dosed in ICU patients during the first 24-48 hours of treatment. Glomerular hyperfiltration syndrome, increased drug volume of distribution, vasopressor use, male sex and hypoalbuminemia are identified risk factor for vancomycin underdosing in ICU patients, among others. To date, bedside estimation of vancomycin volume of distribution is challenging, and new methods for optimizing drug administration are required. The Picco device is a moderately invasive hemodynamic monitoring system, providing parameters that may help estimation of vancomycin pharmacokinetics parameter. The aim of this study is to test whether addition of hemodynamic parameters would improve pharmacokinetics modelling of vancomycin concentration in ICU patients.
Study Type
OBSERVATIONAL
Enrollment
80
Hospices Civils de Lyon - Hôpital de la Croix-Rousse - Réanimation, Surveillance Continue Médicales et Assistance Respiratoire,103 Grande Rue de la Croix-Rousse
Lyon, France
Akaike information criterion as a measurement of goodness of fit of pharmacokinetic modeling of vancomycin serum concentration
All available vancomycin measurements during the first week of treatment will be included in the pharmacokinetics model. All vancomycin dosages up to seven days of treatment will be used in a population pharmacokinetic model and an individual pharmacokinetic model
Time frame: week 1
Rate of patients with under-dosage of vancomycin at day 2 of treatment
under-dosage of vancomycin is defined by a vancomycin serum concentration below 15 mg/l on day 2 of treatment.
Time frame: day 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.